-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were
Search Results
BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50
Robin M. Lally, Elizabeth Reed, and Roksana Zak
Highlights of the NCCN Oncology Research Program
) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle
HSR22-150: Lymph Node Evaluation of Post-Neoadjuvant Rectal Resection Specimens in Rectal Carcinoma
Saman S Karimi and Maria Gonzalez
determine the number of positive lymph nodes as an independent prognostic indicator in Stage II colorectal carcinoma, which prompts adjuvant therapy in these patients. This study aimed to assess the average number of lymph nodes in post-neoadjuvant rectal
CRE24-040: Gluteal Metastasis of Intrahepatic Cholangiocarcinoma: Clinical Case and Literature Review
Natalia de la Puente Mota, Yolanda Gómez Fandiño, Francisco Javier Anguita Ramos, María López López, Mariaclaudia Ocharán Puell, Beatriz Carnero López, Jorge González Ramírez, Adriana Fernández García, and José Conde Vales
diagnosed with intrahepatic cholangiocarcinoma three years prior and was treated with resection and adjuvant therapy involving chemotherapy and radiotherapy. He was referred to the general surgery outpatient clinic by his oncologist for the excision of a
HSR20-102: Quality Outcomes in Colon Cancer
Michelle Moskal and Neeharika S. Makani
, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III
University of Michigan Comprehensive Cancer Center Opportunities for Improvement Project
Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver
Center Educational Forum attendees illustrated a theme related to adjuvant therapy delay. Providers were surprised to learn that as many as 10% of patients were not recorded as receiving adjuvant endocrine therapy. Performance on this measure did not
Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?
Rosalyn A. Juergens and Julie R. Brahmer
. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer . Eastern Cooperative Oncology Group . N Engl J Med 2000 ; 343 : 1217 – 1222 . 20. Mineo TC Ambrogi V
Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin
Roy H. Decker and Lynn D. Wilson
the addition of adjuvant therapy . J Clin Oncol 2005 ; 23 : 7236 – 7237 . 13. Wilson LD Gruber SB . Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence
The Current Status of Combined Radiotherapy and Chemotherapy for Locally Advanced or Resected Pancreas Cancer
Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.
1990 ; 66 : 56 – 61 . 7 Whittington R Bryer MP Haller DG . Adjuvant therapy of resected adenocarcinoma of the pancreas . Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137 – 1143 . 8 Abrams RA . Adjuvant therapy for pancreatic
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass
, adjuvant chemotherapy. 10 Population and institutional studies have shown that adjuvant therapy may confer a survival advantage in some patients with resected colon cancer (eg, those with stage III or high-risk stage II disease). 11 – 14 Furthermore
